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ABSTRACT A mathematical model of the extrinsic or tissue factor (TF) pathway of blood coagulation is formulated and
results from a computational study of its behavior are presented. The model takes into account plasma-phase and
surface-bound enzymes and zymogens, coagulation inhibitors, and activated and unactivated platelets. It includes both
plasma-phase and membrane-phase reactions, and accounts for chemical and cellular transport by flow and diffusion, albeit
in a simplified manner by assuming the existence of a thin, well-mixed fluid layer, near the surface, whose thickness depends
on flow. There are three main conclusions from these studies. (i) The model system responds in a threshold manner to
changes in the availability of particular surface binding sites; an increase in TF binding sites, as would occur with vascular
injury, changes the system’s production of thrombin dramatically. (ii) The model suggests that platelets adhering to and
covering the subendothelium, rather than chemical inhibitors, may play the dominant role in blocking the activity of the TFVIIa
enzyme complex. This, in turn, suggests that a role of the IXa-tenase pathway for activating factor X to Xa is to continue factor
Xa production after platelets have covered the TFVIIa complexes on the subendothelium. (iii) The model gives a kinetic
explanation of the reduced thrombin production in hemophilias A and B.
INTRODUCTION
When the wall of a blood vessel is injured, a variety of
molecules that are embedded in the vessel wall become
exposed to the blood, and this initiates two interacting
processes known as platelet aggregation and coagulation.
The first of these involves platelets, a cellular constituent of
the blood. A platelet can adhere to the damaged tissue and
undergo an activation process that involves changes in the
platelet’s surface membrane and also causes the platelet to
release various chemicals into the blood plasma. The re-
leased chemicals can induce other platelets, which have not
directly contacted the injured wall, to become activated and
able to cohere to one another and to the already wall-
adherent platelets. This is the process of platelet aggrega-
tion. Blood coagulation involves a series of enzymatic re-
actions, a typical one of which cleaves an inactive plasma
zymogen to form an active enzyme. The initial stimulus is
believed to be the formation of a particular molecular com-
plex (tissue factor VIIa) on the injured vessel surface, and
the final enzyme in the series is thrombin, which cleaves the
plasma protein fibrinogen into fibrin monomers. These po-
lymerize and cross-link to form a fibrous mesh on and
between the aggregated platelets to mechanically stabilize
the aggregate. Together, the platelet aggregate and fibrin
mesh constitute the blood clot, and their formation com-
prises hemostasis, the normal response to vessel injury.
These two processes are also believed to be the major
components of thrombosis, a pathological process that in-
volves formation of a clot inside a blood vessel and that can
lead to the complete occlusion of the vessel and consequent
blockage of oxygen and nutrients from important organs.
Understanding these processes and how they are regulated
is of major medical importance. As briefly described above,
platelet aggregation and coagulation may seem to be largely
independent processes that only interact in the end, when
the fibrin mesh forms on the platelet aggregate. In fact, there
are important interactions much earlier in the processes that
couple them. These include the apparently critical role
played by the surface membranes of activated platelets in
promoting certain coagulation reactions and the role that the
coagulation enzyme thrombin plays as a potent platelet
activator.
Figs. 1–3 show the major reactions of the coagulation
process including interactions with platelets. As one can see
from Fig. 1, coagulation involves numerous instances in
which an enzyme produced in one reaction catalyzes the
next reaction. It also involves feed-forward and feedback
loops in which an enzyme produced in one step promotes
(see Fig. 2) or inhibits (see Fig. 3) earlier or later reactions.
Some of the coagulation reactions happen in the plasma, but
several apparently critical reactions involve membrane-
bound enzyme complexes. Despite the extreme importance
of coagulation in normal hemostasis and in pathological
thrombosis, people have only general (and largely un-
proven) ideas about what these different features may be
for—the multitude of steps for signal amplification, the
loops for tight regulation, the involvement of membrane-
bound complexes for spatial localization. Our understand-
ing of the dynamics of the coagulation system remains poor.
The complexity of the biochemical reaction network itself,
the requirement that appropriate phospholipid surfaces on
activated platelets (Mann et al., 1990) be available in order
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that the critical membrane-bound enzyme complexes can
form, and the dependence on flow and diffusion (Gemmell
et al., 1988) for the delivery of the chemical reactants and
platelets to appropriate locations in the developing clot, all
make it very difficult to synthesize a coherent picture of
coagulation dynamics using traditional laboratory ap-
proaches, and make mathematical modeling a potentially
very fruitful complementary tool for studying coagulation.
Below we give a brief review of the coagulation reaction
system describing in words the reactions given schemati-
cally in Figs. 1–3. There are several features of the system
that it is important to keep in mind. One is the presence of
positive feedback loops. Another is the major role played by
surface-bound enzyme complexes, and the role that regula-
tion of the availability of binding sites for these complexes
might play in the overall dynamics. A third is the role the
coagulation enzymes themselves play in up-regulating the
surface binding sites as well as in up-regulating inhibitors of
the coagulation system.
In an earlier paper (Fogelson and Kuharsky, 1998), we
investigated a simple enzyme system with membrane bind-
ing. There we saw that up-regulation of membrane binding-
site density can serve as a biological switch, drastically
changing the response of the system to small amounts of
circulating enzyme. One goal of the current paper is to
explore whether similar switch-like behavior is found in a
much more comprehensive model of coagulation.
Review of the coagulation system
Coagulation is believed to be initiated when tissue factor
(TF) molecules embedded in the vessel wall are exposed by
injury (Nemerson, 1992) (see Fig. 1) and bind plasma
enzyme factor VIIa (fVIIa). The surface-bound complex
TFVIIa activates plasma zymogens fIX and fX into en-
zymes fIXa and fXa (Krishnaswamy et al., 1992; Silverberg
et al., 1977; Zur and Nemerson, 1980). Activated fXa in
turn is a potent activator of fVII into enzyme VIIa (Rad-
cliffe and Nemerson, 1976), particularly when fVII is al-
FIGURE 1 Backbone of the coagulation reaction system. Surface-bound
molecular complexes (TFVIIa on the subendothelium, and VIIIaIXa and
VaXa on the surface of an activated platelet) are indicated by the small
rectangles. The thin arrows indicate movement of a chemical species; the
thick lines with filled arrowheads indicate a molecular or cellular activation
process; and the thick lines with open arrowheads depict the action of the
enzymes that catalyze the activation reactions.
FIGURE 2 Enzymatic feedback in coagulation. The thick lines with
filled arrowheads indicate a molecular or cellular activation process; the
thick lines with open arrowheads indicate enzymatic activity; the dashed
lines with open arrowheads indicate strong enzymatic feedback activity;
and the dotted lines with open arrowheads indicate weak enzymatic feed-
back activity.
FIGURE 3 Chemical inhibition of coagulation. The major inhibitors
(ATIII, APC, and TFPIXa) are indicated with small ellipses and the
species affected by each inhibitor is shown by . Not shown is the
postulated role of adherent platelets in physically covering TF molecules.
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ready bound to TF as TFVII (Rao and Rapaport, 1988).
The TFVIIa and fXa interaction is an example of a surface-
dependent positive feedback loop. Factor Xa also activates
plasma factors V and VIII into Va and VIIIa; each of these
can then serve as the anchor for a membrane-bound enzyme
complex (VIIIaIXa and VaXa) on the surface of an acti-
vated platelet (Krishnaswamy et al., 1993; Mann et al.,
1990). The platelet-bound VIIIaIXa (tenase) complex ac-
tivates X to Xa; Xa binds with Va on a platelet’s surface to
form the VaXa (prothrombinase) complex, which activates
prothrombin (fII) into thrombin (fIIa). While plasma-phase
fXa is a weak activator of prothrombin into thrombin (Ros-
ing et al., 1980), the platelet-bound VaXa complex is a
very potent thrombin activator; its effectiveness is five
orders of magnitude greater (Miletich et al., 1977) than that
of plasma-phase Xa and thus is likely the dominant source
of thrombin activation.
The formation and activity of the VIIIaIXa and VaXa
complexes are critically dependent on the availability of
suitable anionic phospholipid binding sites; these sites are
not present on normally circulating platelets, but are present
on activated platelets. Platelet activation can be induced by
direct contact of platelets with collagens exposed in the
injured vessel tissue, by the action of thrombin, or by other
platelet-secreted plasma-phase chemical messengers like
adenosine diphosphate (ADP) and thromboxane-A2
(TXA2).
Thrombin is the final enzyme produced by the coagula-
tion cascade, and it plays several roles in coagulation. As
mentioned above, it promotes the formation of a fibrin
mesh, and this mechanically stabilizes the platelet aggre-
gates that have formed on the injured vessel. Thrombin also
promotes its own production by activating factors V and
VIII and by activating platelets (Eaton et al., 1986; Monk-
ovic and Tracy, 1990b).
Thrombin also plays at least one more, and quite differ-
ent, role in coagulation. It binds with thrombomodulin
(TM), which is located on the surface of the endothelial
cells that line the undamaged vessel wall. This has two
effects: (1) the bound thrombin is inhibited in its procoagu-
lant role, and (2) the TM-thrombin complex activates
plasma protein C into activated protein C (APC). APC is a
potent anti-coagulant which cleaves factors VIIIa and Va,
thus inactivating them and preventing their serving as co-
factors in the VIIIaIXa and VaXa complexes (Esmon,
1989). Two other major inhibitors of coagulation are anti-
thrombin III (ATIII) and tissue factor pathway inhibitor
(TFPI). ATIII competitively inhibits thrombin and factors
IXa and Xa (Bauer and Rosenberg, 1987), whereas TFPI
binds with fXa to inhibit the activity of the TFVIIa com-
plex (Broze et al., 1990; Rapaport, 1989) and to block the
activity of the fXa that is bound to TFPI. Excellent reviews
of the coagulation pathways can be found in Hemker and
Kessels (1991), Jesty and Nemerson (1995), and Mann et al.
(1990).
Previous models
Nesheim and coworkers (Nesheim et al., 1984, 1992) ex-
plored a steady-state model of prothrombinase activity
which involves two phases, one corresponding to the bulk
solution, and the other to thin shells surrounding phospho-
lipid membranes. More recent modeling from the same
laboratory (Jones and Mann, 1994) looked at dynamic in-
teractions among a number of the coagulation enzymes and
zymogens. These new models ignored inhibition and, im-
portantly, assumed a great excess of phospholipid, and
therefore did not address the possible regulatory role played
by phospholipid surfaces in controlling the coagulation re-
actions. Willems et al. (1991) studied a dynamic model of
thrombin production in plasma, allowing for inhibition by
APC and exogenous hirudin. The stimulus in the system is
a brief pulse of fXa, and a threshold response to this
stimulus was reported. The model inputs included phospho-
lipid concentration, but the effect of this concentration on
system behavior was not reported. Baldwin and Basmadjian
(1994) modeled the part of the coagulation network that
includes activation of zymogens fX and prothrombin, feed-
back activation of cofactors fV and fVIII by thrombin, and
degradation of fXa and thrombin due to inhibitors. Their
model includes transport of chemical species to/from a
surface consisting of the membranes of platelets assumed to
be adherent to the vessel wall. This membrane is assumed to
be present in large excess. TFVIIa activation of fX and fIX
are not included, and instead exogenous fIXa is introduced.
The main results of the paper are (i) the existence of
multiple steady-state solutions at intermediate levels of
mass transport, and (ii) dynamic results that indicate very
slow development of thrombin at low mass-transfer rates,
very little development of thrombin at high mass-transfer
rates, and, depending on the initial concentration of throm-
bin, little or substantial production of thrombin over periods
relevant for hemostasis, at intermediate mass-transfer rates.
Jesty et al. (1993) analyzed a simple system which involves
two zymogen-enzyme pairs in a positive feedback loop with
inhibition. In their system, each zymogen is activated by the
enzyme of the other zymogen-enzyme pair, and both en-
zymes are subject to first-order inactivation. Their main
result was that the system has a threshold. If the product of
activation rates is less than the product of inactivation rates,
then the system’s response to a stimulus (an increment of
enzyme) quickly decays. If the product of activation rates
exceeds the product of inactivation rates, the same stimulus
produces a large conversion of zymogen to enzyme. Bel-
trami and Jesty (1995) extended this analysis to larger
systems made up of multiple interacting feedback loops.
These results are interesting but limited because the analysis
is for solution-phase reactions only; no account is taken of
surface binding or transport of reactants to and from reac-
tive surfaces, even though surface reactions seem to play a
major regulatory role in coagulation. In earlier work (Fo-
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gelson and Kuharsky, 1998), we considered an extension of
the Jesty-Beltrami approach, which includes both solution-
phase and membrane-phase reactions, and in which the
concentrations of membrane binding-sites are limited and
treated as control variables. As mentioned above, we found
that up-regulation of membrane binding-site density can
serve as a biological switch modulating the threshold value
of the system, and changing the status of the system from
‘off’ (in which even large amounts of circulating enzyme
produce only a transient decaying response) to ‘on’ (in
which even small amounts of circulating enzyme produce a
large and sustained response). This result holds when the
preponderance of enzymatic activity is vested in the mem-
brane-bound enzymes, as seems to be the case in coagula-
tion. It holds in models in which the two phases are assumed
to be well mixed (as in the limit of very fast diffusion) and
in models in which there is diffusion at physiological rates
between the solution and membrane phases.
In the current paper we look at a much more comprehen-
sive model of coagulation biochemistry that also takes into
account, in a simplified way, the effect of transport of
chemicals and platelets and the competing effects of acti-
vated platelets in providing pro-coagulant surfaces and in
covering the exposed injury by adhering to it.
MODEL ASSUMPTIONS
In this section, we describe a mathematical model of the tissue factor
pathway of blood coagulation that takes into account plasma-phase and
phospholipid-membrane-bound enzymes and zymogens, coagulation in-
hibitors, and activated and unactivated platelets. The model includes both
plasma-phase and membrane-phase reactions. We consider events that
occur after exposure of an area of subendothelium of axial length L and
circumferential width W on the surface of a vessel of radius R. We assume
that all reactions of interest occur in a thin boundary layer shell above the
injured surface. We assume that all species (plasma-phase and membrane-
phase) in this shell are well mixed, and it follows from this assumption that
all reactions can be described using ordinary differential equations in time.
Initially the shell is filled only with fluid and chemicals, and has a
thickness determined by the relative influence of zymogen transport by
radial diffusion and axial convection. For the situations considered in this
paper, this chemical boundary layer thickness ranges from 0.4 to 2.0 m.
As time progresses, platelets enter the region and adhere to the subendo-
thelium or aggregate on already adherent platelets, and this increases the
total thickness and volume of the shell.
Flow and diffusion combine to bring proteins into the shell from
upstream and to carry them downstream, away from the damaged wall.
These effects are incorporated into the model in a simple way by assuming
that each plasma-phase protein is delivered to or removed from the shell at
a rate proportional to the difference between its concentration within the
shell and its concentration far outside of the shell. Hence, the equations that
describe how the concentrations of plasma-phase proteins change with time
involve terms of the form kflowc (cout  c) where c is the concentration
within the shell, cout is the concentration far outside of the shell, and kflowc
denotes the rate function. The value of kflowc depends on flow and diffusion
parameters and on other factors described in Appendix A.
Unactivated platelets are also transported by flow and diffusion, and, in
addition, can undergo an activation process and can adhere to the damaged
vessel wall and to other adherent platelets. The equation that governs how
the concentration of unactivated platelets changes with time involves a
term kflowp ([PL]out  [PL]) with [PL] and [PL]out the concentrations of
unactivated platelets in and outside of the boundary layer, respectively. The
rate function kflowp for platelet transport has a different value than that for
zymogen and enzyme transport. This is because we take the platelet
boundary layer thickness to be 2–3 m, the distance over which platelets
can attach to one another because of their pseudopodia (Frojmovic et al.,
1990), and this is greater than the thickness of the zymogen/enzyme
chemical boundary layer as determined from the protein’s Peclet number.
Note that the units of kflowc and kflowp are s1. This differs from mass-transfer
coefficients often used in the engineering literature (see, for example,
Baldwin and Basmadjian (1994); Cussler (1984)) where the mass transfer
coefficient k has units of cm/s. The reason for the difference is that kflowc
(cout  c) describes transport into the volume of the shell, whereas in the
references cited, k(cout  c) describes transport to a surface. Further
discussion of the relationship between our kflowc and the mass-transfer
coefficient k is given in Appendix A.
Assumptions about platelets
Three different populations of platelets are considered in the model: (i)
unactivated and free in solution, (ii) activated and attached directly to the
subendothelium, and (iii) activated but not attached directly to the suben-
dothelium. Only the unactivated platelets are treated as free to move out of
the shell because of the flow; we think of the activated platelets in the shell
that are not attached directly to the subendothelium as part of a wall-bound
aggregate. Unactivated platelets can become activated in three ways: (i) by
directly reacting with the subendothelium and binding to it, (ii) by exposure
to sufficiently high concentrations of the coagulation enzyme thrombin,
and (iii) by exposure to other already activated platelets. The last mecha-
nism is used as a surrogate for platelet activation by chemicals (e.g., ADP)
secreted by platelets but not explicitly included in the model. The two
populations of activated platelets provide binding sites with which some of
the coagulation zymogens and enzymes can react. In taking into account
the role of the activated platelets in the coagulation reactions, we regard
them as uniformly distributed over the volume of the shell. For other
purposes, it is useful to think of the activated platelets as stacked in layers.
We regard each wall-adherent platelet as covering a specified area of the
exposed subendothelium. To compute the current number of layers, we
calculate the number of activated platelets in the shell (the concentration of
activated platelets times the shell volume) and divide this by the maximum
number of platelets that can directly bind to the subendothelium (the
subendothelial area L  W divided by the area covered by a single platelet).
Each successive platelet layer increases the size of the shell and the volume
in which the chemicals interact. This volume consists of the chemical
boundary layer above the platelet layers and the spaces between platelets
within the layers. Because the part of this volume between the adherent
platelets is relatively sheltered from the flow, the overall rate of flow-
mediated delivery of zymogen to the shell or flow-mediated removal of
enzyme from the shell decreases as the number of platelet layers increases.
This is reflected in a reduction in the parameters kflowc and kflowp from their
initial values by a factor equal to the current ratio of volume in the
chemical boundary layer to the volume in the chemical boundary layer and
in the spaces between the platelets. Because the model does not provide for
shear-induced removal of platelets as a mechanism for limiting aggregate
size, we explicitly limit the number of platelet layers that are allowed to
form, usually to four or fewer.
Assumptions about reactants
1. Factors VII and VIIa can bind to TF on the exposed subendothelium
(Radcliffe and Nemerson, 1976). Factor Xa activates factor VII in
plasma as well as when factor VII is bound to TF (Radcliffe and
Nemerson, 1975). We assume that Xa binds to the TFVII complex
directly from plasma without having to first bind to the subendothelium.
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2. Factors IX and X can be activated to IXa and Xa respectively by the
TFVIIa complex on the subendothelium (Zur and Nemerson, 1980;
Silverberg et al., 1977). This is the only source of factor IXa. Factor X
can also be activated by the VIIIaIXa (tenase) complex on the surface
of an activated platelet. Factors X and IX are assumed to attach to
TFVIIa directly from plasma.
3. Factors V and VIII can be activated to factors Va and VIIIa by thrombin
in plasma and by thrombin and factor Xa on the surfaces of activated
platelets (Vehar and Davie, 1980; Monkovic and Tracy, 1990b).
4. The inhibitors of the coagulation reactions that we include in the model
are antithrombin III (ATIII), activated protein C (APC), and tissue
factor pathway inhibitor (TFPI). Since the concentration of ATIII is
very high in plasma, we assume it acts in a first-order manner to
inactivate plasma factors IXa, Xa, and thrombin. APC is assumed to
bind directly from solution to platelet-bound factors Va and VIIIa and
to permanently inactivate them (Solymoss et al., 1988; Walker et al.,
1987) with second-order kinetics. Because APC is produced by a
complex of thrombin and thrombomodulin (TM) on healthy endothelial
cells near the damaged wall, we regard the concentration of APC as a
function of the quantity of thrombin that has left the shell. To account
for the time it takes thrombin to leave the shell, bind to TM, and activate
protein C, and the time for APC to enter the shell, we assume that there
is a lag tlag and that the APC level at time t depends on the thrombin
level at time t  tlag. TFPI must first bind to factor Xa, and then the
complex TFPIXa binds to the TFVIIa complex and inhibits it (Broze
et al., 1988).
Assumptions about the binding of proteins to
surfaces
1. Factors VII and VIIa compete for the TF binding sites on the suben-
dothelium.
2. Factors IX and X compete for the TFVIIa complex on the subendo-
thelium.
3. Each zymogen/enzyme pair, II/IIa, V/Va, VIII/VIIIa, and X/Xa has
distinct binding sites on activated platelets for which the zymogen and
enzyme compete. For IX/IXa, we consider two scenarios: one in which
IX/IXa compete for binding sites, and one in which there is also a set of
binding sites for IXa alone (Ahmad et al., 1989). We refer to these as
shared and IXa-specific binding sites, respectively.
Our model includes the possibility that the activity of the TFVIIa
complex decreases as platelet deposition on the injured tissue increases.
That is, we allow for the possibility that as platelets cover the exposed
subendothelium, they physically block the activity of the TFVIIa com-
plex. This has important consequences regarding the behavior of the model
system and the experiments and reasoning that led us to include this
possibility are discussed below.
Notation
The coagulation reactions we consider are listed in Tables 1–6. Zi and Ei
refer to zymogen i and enzyme i in solution, and Zim and Eim refer to the
membrane-bound versions of these proteins (e.g., E7m refers to the TFVIIa
complex and E5m refers to fVa bound to the platelet surface). Concentra-
tions are denoted in a similar way but with lower-case z and e. TF, P2, P5,
P8, P9, and P10 refer to tissue factor and the binding sites on activated
platelets for prothrombin/thrombin and factors V/Va, VIII/VIIIa, IX/IXa,
and X/Xa, respectively; [TF], p2, p5, p8, p9, and p10 refer to the concen-
trations of these binding sites; and N5pl, N10pl , N8pl, N9pl, and N2pl refer to the
number of these receptors expressed on the surface of a platelet when the
platelet is activated. Quantities pertaining to the IXa-specific binding sites
are denoted in a similar way but with an additional superscript *, e.g., p*9
is the concentration of IXa-specific sites, and e9m, is the concentration of
IXa bound to these sites. We denote a complex of Zi and Ej by ZiEj and
its concentration by [ZiEj]. Special symbols are used for the platelet-
bound tenase VIIIaIXa and prothrombinase VaXa complexes, TEN 
VIIIaIXa and PRO  VaXa; [TEN] and [PRO] denote their respective
concentrations. Unactivated platelets are denoted by PL; activated platelets
attached to the subendothelium by PLas; and activated platelets not attached
to the subendothelium by PLav. The respective platelet concentrations are
[PL], [PLas], and [PLav]. The inhibitors are denoted APC and TFPI with
concentrations [APC] and [TFPI]. The full set of model equations is listed
in Appendix B. In the following paragraphs, we use several of the equa-
tions to explain the different types of terms that appear in the full set of
equations.
Terms in the model equations
Equation 4 in Appendix B is:
de2m
dt  k2
onc2p2 z2mtot e2mtot
k2offe2m k7catZ2mPRO
k13cat k13Z5mE2m k13z5me2m
k15cat k15Z8mE2m k15z8me2m
Here, the term k2on e2 (p2  z2mtot  e2mtot) gives the rate at which the
plasma-phase enzyme E2 (thrombin) binds to the surface of an activated
platelet; p2 is the total volume concentration of binding sites for Z2 and E2
on the activated platelets in the shell, from which the concentration of
occupied binding sites z2mtot  e2mtot is subtracted to give the concentration
of unoccupied sites. The quantities z2mtot and e2mtot denote the concentrations
TABLE 1 Reactions on subendothelium
Reaction Reactants Complex Product M1 s1 s1 s1 Note
VII binding with TF Z7, TF Z7m k7on  5.0  107 k7off  5.0  103 a
VIIa binding with TF E7, TF E7m k7on  5.0  107 k7off  5.0  103 a
Xa activation of TFVII E10, Z7m Z7mE10 E7m k2  5.0  106 k2  1.0 k2cat  5.0 b
IIa activation of TFVII E2, Z7m Z7mE2 E7m k3  3.92  105 k3  1.0 k3cat  6.1  102 c
TFVIIa activation of X E7m, Z10 Z10E7m E10 k8  8.95  106 k8  1.0 k8cat  1.15 d
TFVIIa activation of IX E7m, Z9 Z9E7m E9 k9  8.95  106 k9  1.0 k9cat  1.15 e
(a) Kd  1.0  1010 M (Nemerson, 1992).
(b) k2cat  5.0 s1 and KM  1.2  106 M (Butenas and Mann, 1996).
(c) k3cat  6.1  102 s1 and KM  2.7  106 M (Butenas and Mann, 1996).
(d) k8cat  1.15 s1 and KM  4.5  107 M (Mann et al., 1990).
(e) We assume that the reaction constants for TFVIIa activation of fIX are the same as for TFVIIa activation of fX.
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of platelet-bound prothrombin and thrombin, respectively, along with their
platelet-bound complexes, so z2mtot  z2m  [Z2mPRO] and e2mtot  e2m 
[Z5mE2m]  [Z8mE2m]. The term k2off e2m is the rate of dissociation of
thrombin from the platelet surface. The terms (k13cat  k13 ) [Z5mE2m] and
k13 z5m e2m pertain to the association/dissociation of Z5m with E2m on the
platelet surface and the enzymatic activation of Z5m to E5m. The terms (k15cat
k15 ) [Z8mE2m]  k15 z8m play a similar role in describing the interactions of
thrombin with platelet-bound Z8m.
The new types of terms in Eq. 5:
dz5
dt k5
onz5p5 z5mtot e5mtot k5offz5m
k12z5e2 k12Z5E2
N5
dPLas PLav
dt  kflow
c z5out z5
include k12 z5 e2, which is the rate at which plasma-phase fV and plasma-
phase thrombin bind to form the Z5E2 complex, and k12 [Z5E2], which is
the rate at which this complex dissociates. The term N5d([PLas]  [PLav])/dt
gives the rate of appearance of fV due to its release by platelets upon
activation. The final term, kflowc (z5out  z5), describes the transport of fV
into the shell by flow and diffusion.
Equation 49
dPLav
dt kpla
 psub PLasPLav
kpla PLas kc2
actPLAe2
kplaactPLas PLavPL,
describes the rate at which the concentration of activated platelets not
attached to the subendothelium changes. The term kpla (psub  [PLas-
])[PLav] is the rate of deposition of activated platelets onto the subendothe-
lium; (psub  [PLas]) is the concentration of available platelet binding sites
on the subendothelium and kpla is the second-order rate constant for
deposition. The term kpla [PLas] describes platelet detachment from the
subendothelium. The term ke2
act [PL] A(e2) describes irreversible activation
of unactivated platelets by thrombin at a rate which depends on the
thrombin concentration. We have experimented with different choices of
the function A(e2), using either A(e2)  e2/(e2pla  e2) or A(e2)  H(e2 
e2pla) with very little difference in results. Here, e2pla is a prescribed level of
thrombin concentration (e.g., 1 nM) characteristic of the thrombin concen-
trations that affect platelets, and H(x) is the step function, which has value
0 for all x 	 0 and value 1 for all x 
 0. For the simulations reported in
this paper, we used the first version of A(e2). The final term, kplaact([PLas] 
TABLE 3 Binding to platelet surfaces
Reaction Reactants Products M1 s1 s1 Note
Factors IX Z9, P9 Z9m k9on1.0  107 k9off2.5  102 a
Factors IXa E9, P9 E9m k9on1.0  107 k9off2.5  102 a
Factors IXa E9, P*9 E9m, k9on1.0  107 k9off2.5  102 b
Factors X Z10, P10 Z10m k10on1.0  107 k10off2.5  102 a
Factors Xa E10, P10 E10m k10on1.0  107 k10off2.5  102 a
Factors V Z5, P5 Z5m k5on5.7  107 k5off0.17 c
Factors Va E5, P5 E5m k5on5.7  107 k5off0.17 c
Factors VIII Z8, P8 Z8m k8on5.0  107 k8off0.17 d
Factors VIIIa E8, P8 E8m k8on5.0  107 k8off0.17 d
Factors II Z2, P2 Z2m k2on1.0  107 k2off5.9 e
Factors IIa E2, P2 E2 k2on1.0  107 k2off5.9 e
(a) For fIX binding to platelets, Kd  2.5  109 M (Ahmad et al., 1989), and for fX binding to platelets, Kd has approximately the same value (Walsh,
1994). For fX binding to PCPS vesicles, the on-rate is about 107 M1 s1 and the off-rate is about 1.0 s1 (Krishnaswamy et al., 1988), giving a dissociation
constant of about 107 M. To estimate on- and off-rates for the higher-affinity binding of fX to platelets, we keep the on-rate the same as for vesicles and
adjust the off-rate to give the correct dissociation constant. The rates for fIX binding with platelets are taken to be the same as for fX binding.
(b) We assume binding constants for fIXa binding to the specific fIXa binding sites are the same as for shared sites.
(c) fV binds with high-affinity to phospholipids (PCPS) (Krishnaswamy et al., 1988) and we use the same rate constants reported there to describe fV
binding to platelets.
(d) The Kd for fVIII binding with platelets is taken from (Nesheim et al., 1988). We set the off-rate k8off for fVIII binding to platelets equal to that for fV
binding to platelets, and calculate the on-rate k8on.
(e) For prothrombin interactions with platelets, Kd is reported to be 5.9  107 M (Mann, 1994). We choose k2off and set k2on  k2off/Kd.
TABLE 2 Reactions in the plasma
Reaction Reactants Complex Product M1 s1 s1 s1 Note
Xa activation of VII Z7, E10 Z7E10 E7 k1  5  106 k1  1.0 k1cat  5.0 a
IIa activation of VII Z7, E2 Z7E2 E7 k18  3.92  105 k18  1.0 k18cat  6.1  102 b
IIa activation of V Z5, E2 Z5E2 E5 k12  1.73  107 k12  1.0 k12cat  0.23 c
IIa activation of VIII Z8, E2 Z8E2 E8 k14  2.64  107 k14  1.0 k14cat  0.9 d
(a) k1cat  5.0 s1 and KM  1.2  106 M (Butenas and Mann, 1996).
(b) k18cat  6.1  102 s1 and KM  2.7  106 M (Butenas and Mann, 1996).
(c) k12cat  0.23 s1 and KM  7.17  108 M (Monkovic and Tracy, 1990b).
(d) k14cat  0.9 s1 (Hill-Eubanks and Lollar, 1990) and KM  2  107 M (Lollar et al., 1985).
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[PLav])[PL] corresponds to the activation of unactivated platelets through
contact with activated platelets. As noted before, we regard this activation
mechanism as a surrogate for activation by platelet-released agonists such
as ADP and TXA2.
In Eq. 12,
de7m
dt  k7
one7TF e7mtot z7mtot k7offe7m
k2catZ7mE10 k3catZ7mE2
k8 k8catZ10E7m k8z10e7m
k9 k9catZ9E7m k9z9e7m
k11TFPIE10e7m
k11TFPIE10E7m e7m
p
1 p
the variable p is the fraction of the subendothelial surface area covered by
platelets (p  [PLas]/psub), p is the rate of change of p; and the expression
p/(1  p)  (1  p)/(1  p) is the fractional rate of change of
uncovered subendothelial area. The last term in the equation says that the
concentration of TFVIIa decreases at a fractional rate equal to the frac-
tional rate of decrease of uncovered subendothelial area. This term em-
bodies our assumption that as platelets bind to the subendothelium the
number of TF molecules (and complexes involving TF) available to par-
ticipate in the coagulation process decreases and therefore the concentra-
tion of available TF molecules in the shell also decreases. A similar term
appears in each equation for a species that involves TF.
Parameter evaluation
To do simulations with the model system, we must specify values of the
kinetic parameters, initial concentrations for all species, and the upstream
concentration (i.e., the concentration outside of the shell) for all plasma-
phase species. For zymogens, the initial and upstream concentrations are
set to their normal plasma concentrations. All enzyme and complex con-
centrations are initially set to zero except for the concentration of fVIIa
(e7), which is set to 1% of the normal fVII concentration. Typical values of
these parameters are given in Tables 1–7. In some simulations different
values are used, and this is indicated in the description of those simulations.
It is typical for enzymatic reactions that literature values are available
for the Michaelis-Menton parameter KM  (k  kcat)/k and the turnover
number kcat but not for k and k separately. In this situation, we choose
a value for k in the range (0.1–10.0 s1) in which most known enzyme
reverse rates lie, and then calculate the corresponding k  (k  kcat)/KM.
Similarly, for binding reactions, the dissociation constant Kd  koff/kon is
often available, whereas the separate on- and off-rates kon and koff are not.
Again, we choose a value for koff (usually 1.0) and compute the corre-
TABLE 4 Reactions on platelet surfaces
Reaction Reactants Complex Product M1 s1 s1 s1 Note
Xa activation of V Z5m, E10m Z5mE10m E5m k5  1.0  108 k5  1.0 k5cat  4.6  102 a
IIa activation of V Z5m, E2m Z5mE2m E5m k13  1.73  107 k13  1.0 k13cat  0.23 b
Xa activation of VIII Z8m, E10m Z8mE10m E8m k6  5.1  107 k6  1.0 k6cat  2.3  102 c
IIa activation of VIII Z8m, E2m Z8mE2m E8m k15  2.64  107 k15  1.0 k15cat  0.9 d
VIIIa binding with IXa E8m, E9m TEN kten  1.0  108 kten  0.01 e
VIIIa binding with IXa* E8m, E9m, TEN* kten  1.0  108 kten  0.01 e
Va binding with Xa E5m, E10m PRO kpro  1.0  108 kpro  0.01 e
VIIIaIXa activation of X Z10m , TEN Z10m TEN E10m k4  1.31  108 k4  1.0 k4cat  20.0 f
VIIIaIXa* activation of X Z10m , TEN* Z10m TEN* E10m k4  1.31  108 k4  1.0 k4cat  20.0 f
VaXa activation of II Z2m, PRO Z2mPRO E2m k7  1.03  108 k7  1.0 k7cat  30.0 g
(a) k5cat  0.046 s1 and KM  10.4  109 M (Monkovic and Tracy, 1990a).
(b) The rate constants for thrombin activation of fV on platelets are assumed to be the same as in plasma.
(c) k6cat  0.023 s1 and KM  2.0  108 M (Lollar et al., 1985).
(d) The rate constants for thrombin activation of fVIII on platelets are assumed to be the same as in plasma.
(e) The formation of the tenase and prothrombinase complexes is assumed to be very fast with Kd  1.0  1010 M (Mann, 1987).
(f) k4cat  20 s1 and KM  1.6  107 M (Rawala-Sheikh et al., 1990).
(g) k7cat  30 s1 and KM  3.0  107 M (Nesheim et al., 1992).
TABLE 5 Inhibition reactions
Reaction Reactants Complex Product M1 s1 s1 s1 Note
APC inactivation of VIIIa APC, E8m APCE8m E8m,in k17  1.2  108 k17  1.0 k17cat  0.5 a
APC inactivation of Va APC, E5m APCE5m E5m,in k16  1.2  108 k16  1.0 k16cat  0.5 a
TFPI binding with Xa TFPI, E10 TFPIE10 k10  1.6  107 k10  3.3  104 b
TFPIXa binding with TFPIE10 TFPIE10E7m k11  1.0  107 k11  1.1  103 b
TFVIIa E7m
ATIII inactivation of IXa E9 E9in k9in  0.1 c
ATIII inactivation of Xa E10 E10in k10in  0.1 c
ATIII inactivation of IIa E2 E2in k2in  0.2 c
(a) For inhibition of fVa by APC, k16cat  0.45 s1 and KM  12.5  109 M (Solymoss et al., 1988). We assume the same reaction rates for the inhibition
of fVIIIa by APC.
(b) From Jesty et al. (1994).
(c) We estimate these parameters based on the half-lives of factors IXa, Xa, IIa in plasma (Rosenberg and Bauer, 1994).
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sponding kon  koff/Kd. We set koff to a smaller value, if necessary, to keep
kon from exceeding the diffusion-limited rate of about 108 M1 s1.
We model platelet deposition as a second-order reaction between plate-
lets and binding sites on the subendothelium, and estimate the rate constant
kpla for this reaction from experimental data. Although we have found no
data for platelet deposition on subendothelial regions of the small size we
consider, we can extract estimates of the deposition rate from macroscopic-
scale studies such as Turitto and Baumgartner (1979) and Turitto et al.
(1980). In these studies, the percent of surface coverage was measured for
a number of thin vessel sections at distances x between 3.5 and 10 mm from
the upstream end of the exposed subendothelium. The average of these
measurements was computed for times ranging from 1 to 40 min, and
initial rates of deposition were also calculated. These initial rates are
unlikely to be confounded by effects on adhesion of upstream thrombus
growth, and so give cleaner data for our purposes here. The same papers
present theoretical formulas in which the deposition rate decreases with
axial distance according to the power law x1/3. We use this power law to
extrapolate the measured deposition rates at x  5–10 mm to the position
x  10 m relevant for our simulations, and then use these extrapolated
rates to estimate the time needed for 95% of our small subendothelial
region to be covered. We find that these times fall in the range 3–5 min,
compared to times of 30–40 min at the far downstream locations at which
Turitto and coworkers made their measurements. We therefore adjust kpla
to 2  1010 M1 s1 so that our model subendothelium is completely
covered by platelets in about 5 min. We note that this deposition rate is
about threefold slower than that reported in Hubbell and McIntire (1986)
for 10 m by 10 m regions of a collagen-coated glass surface under
similar flow conditions. Note that kpla is the rate constant for adhesion to
the surface of platelets that are already in the reaction shell, while kflowp
determines the transport of platelets into the shell.
In the model, three terms contribute to platelet activation, and the rate
of change of the activated platelet concentration (both wall-adherent and
not) is found by adding Eqs. 48 and 49:
dPLas PLav
dt
kpla psub PLas kc2act e2e2pla e2
kplaactPLas PLavPL
To estimate ke2
act, we fit an exponential to the data in Gear (1994) (p. 290)
which shows the rate of disappearance of platelet singlets (as doublets and
larger platelet clusters form) in a quenched-flow experiment following
administration of 10 nM thrombin. The calculated time constant of 0.34
s1 estimates the rate of singlet disappearance at a thrombin concentration
of 10 nM. We estimate e2pla as roughly 1 nM, and equating our expression
for the rate of thrombin-induced activation (with e2  10 nM and e2pla  1
nM) to this calculated rate, we infer that ke2
act  0.37 s1. This value
underestimates somewhat the rate of maximal platelet activation by this
thrombin concentration, since only a fraction of activated platelets collide
and form doublets during Gear’s experiment. We estimate the maximal rate
of thrombin-induced activation as about 0.5–1.0 s1. Gear (1994) also
gives the maximum rate of ADP-induced singlet disappearance as 0.34 s1
with the half-maximal rate corresponding to an ADP concentration of
about 2 M. Hubbell and McIntire (1986) estimate the average ADP
concentration around a small thrombus to be between 0.3 and 0.8 M
depending on shear rate, and this gives a rate of singlet disappearance
between .05 and 0.1 s1. The corresponding rate in the equation above is
kplaact([PLas]  [PLav]). Noting that [PLas] can be as high as psub  2.2  1010
M, and that [PLas]  [PLav] can be somewhat higher than this, we estimate
kplaact as about 3  108 M1 s1 to give an activation rate in the middle of the
range 0.05 to 0.1 s1. With these estimates for ke2
act and kplaact, and with kpla
determined as described above, activation of platelets occurs predomi-
nantly through contact with the subendothelium during the first 240 s of
our simulations, after which time activation by thrombin predominates.
The variables in the model are volume concentrations. We convert
surface densities into volume concentrations as follows: For TF and its
complexes on the subendothelium, the surface density (e.g., fmol/cm2) is
converted into a concentration by dividing it by the height h of the shell.
To determine the volume concentrations of platelet-surface binding sites,
TABLE 6 Platelet responses
Reaction Reactants Products M1 s1 s1 Note
Unactivated platelet binding to SE PL, Psub PLas kpla  2  1010 kpla  0.0 a
Activated platelet binding to SE PLav, Psub PLas kpla  2  1010 kpla  0.0 a
Platelet activation by platelet in solution PL, PLav 2 PLav kplaact  3  108 b
Platelet activation by platelet on SE PL, PLas PLav, PLas kplaact  3  108 b
Platelet activation by thrombin PL, E2 PLav kc2
act  A(e2)  0.50 b
(a) Estimated from data in Turitto and Baumgartner (1979) and Turitto et al. (1980) as described in text.
(b) Estimated from data in Gear (1994) as described in text.
TABLE 7 Normal concentrations and surface binding site
numbers
Prothrombin: z2out 1.4 M a
Factor V: z5out 0.01 M b
Factor VII: z7out 0.01 M a
Factor VIIa: e7out 0.1 nM c
Factor VIII: z8out 1.0 nM a
Factor IX: z9out 0.09 M a
Factor X: z10out 0.17 M a
TFPI: [TFPI]out 2.5 nM d
Platelet: [PL]out 2.5  105/mm3 e
N2pl 2000 f
N5pl 3000 g
N8pl 450 h
N9pl 250 i
N9pl, 250 i
N10pl 2700 j
(a) From Mann et al. (1990).
(b) From Mann et al. (1991).
(c) Morrissey (1995) suggests that normal plasma concentration of fVIIa is
about 1% of the normal fVII concentration.
(d) From Novotny et al. (1991).
(e) From Weiss (1975).
(f) From Brass et al. (1994).
(g) From Walsh (1994).
(h) From Nesheim et al. (1988).
(i) From Ahmad et al. (1989).
(j) From Mann et al. (1992).
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we multiply the relevant platelet concentration by the number of binding
sites per platelet, so, for example, p9  N9pl ([PLas]  [PLav]).
In order to compute numerical solutions of the model equations, we first
nondimensionalize the equations, which has the effect of tremendously
reducing the range of values taken on by model variables. To solve the
nondimensionalized equations, we use methods for stiff ordinary differen-
tial equations implemented in the software package LSODE (Hindmarsh,
1983). We performed careful convergence studies, varying the numerical
time step, to ensure the accuracy of our numerical solutions. A single
10-min simulation takes about 38 s on a SUN Ultra 60 workstation (Sun
Microsystems, Palo Alto, CA).
RESULTS
In this section, we present results of computational experi-
ments exploring the behavior of the model system devel-
oped in the previous section. Unless indicated otherwise, the
parameter values used are those listed in Tables 1–7 and we
refer to these, for brevity, as standard values.
Dependence on surface binding site densities
Motivated by our analysis (Fogelson and Kuharsky, 1998)
of a simple zymogen/enzyme system which showed the
importance of the density of membrane binding sites in
controlling the system’s responsiveness, we conducted a
series of computational experiments differing from one an-
other only in the prescribed density of TF, and we computed
the resulting thrombin production. We did this for each of
several shear rates. The results are shown in Fig. 4 a and
indicate that a small change in TF density can induce an
increase of thrombin concentration of between three and
four orders of magnitude. The thrombin concentrations
achieved at densities just above threshold are greater than 1
nM, a concentration at which thrombin has profound effects
on platelets (Hubbell and McIntire, 1986). These results
show that TF density functions as a switch for the model’s
overall response.
In Fig. 4 b, we show results of a different kind of binding-
site-density experiment. For these experiments, the TF den-
sity was kept fixed at a value of 15 fmol/cm2 which from
Fig. 4 a we see is above threshold for all shear rates between
100 and 1500 s1, and the density of binding sites on the
surfaces of activated platelets was varied. For each experi-
ment, the standard values of platelet binding site numbers
(e.g., N9pl) were multiplied by a common factor, and we
looked at the resulting thrombin concentration as a function
of this multiplier. As Fig. 4 b shows, there is again a very
steep increase in response as the multiplier is increased from
about 0.5 to 1.0 (which corresponds, for example, to a
change in fV binding site number from 1500 to 3000 per
platelet). This behavior is seen at all shear rates examined.
It is interesting to note that the standard values of platelet
binding site densities are just above the computed threshold
levels.
Dependence on flow shear rate
Fig. 5 a shows the time course of thrombin concentration at
several shear rates for a TF density of 15 fmol/cm2 and for
standard values of all parameters. We see that for all shear
rates in the range 100 to 1500 s1, the thrombin concentra-
tion remains low for 3–5 min, and then increases rapidly
over a time interval of about 40–50 s (for example, the
interval between 220 and 270 s at shear rate 100 s1) and
reaches a level of 18–70 nM within 600 s. The thrombin
concentrations reached at 600 s increase as the shear rate is
decreased in this range. Fig. 5 b shows that thrombin levels
for a TF density of 1 fmol/cm2 remain very low and decay
slowly.
Hemophilias A and B
These are clinical bleeding disorders associated with defi-
cient quantities of factors VIII and IX, respectively. Our
FIGURE 4 Dependence of thrombin concentration at 600 s on (a) the density of TF on the subendothelium at shear rates of 100, 500, and 1500 s1, (b)
the densities of binding sites on platelets. The value Multiplier 1 corresponds to the standard values of these densities.
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first attempts to simulate these disorders failed, and we
determined that this was due to continued significant pro-
duction of fXa by the TFVIIa complex on the subendothe-
lium. As we explain further below, the chemical inhibitor
thought to be responsible for shutting off the TFVIIa
complex, namely TFPIXa, is present in concentrations far
too small to actually accomplish this. It was these observa-
tions which led us to add to the model the possibility that
platelet deposition on the subendothelium physically inhib-
its the activity of the TFVIIa complex.
In Fig. 6, we show results of model simulations with and
without the physical inhibition of TFVIIa by wall-adherent
platelets, for a TF density of 15 fmol/cm2 and standard
parameter values. Fig. 6, a–c, depicts results with physical
inhibition of TFVIIa and shows significant reductions in
thrombin concentration for both hemophilia A and hemo-
FIGURE 5 Time course of thrombin concentration for shear rates of 100, 500, and 1500 s1 for TF density (a) 15 fmol/cm2 and (b) 1 fmol/cm2. Note
different scales.
FIGURE 6 Hemophilia. Time course of thrombin concentration for different levels of fVIII and fIX and different shear rates and TF density 15 fmol/cm2.
Normal denotes normal levels of fVIII and IX. HemA denotes 1% of normal fVIII and normal fIX. HemB denotes 1% of normal fIX and normal fVIII.
Frames (a) 100 s1, (b) 500 s1, and (c) 1500 s1 are for simulations in which platelet deposition blocks TFVIIa activity. Frames (d) 100 s1, (e) 500
s1, and (f) 1500 s1 are for simulations in which platelet deposition does not block TFVIIa activity.
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philia B at various shear rates. The degree of reduction
increases substantially with increasing shear rate. In each
case the reduction for hemophilia A (fVIII deficiency) is
more pronounced than for hemophilia B, in agreement with
clinical observations. Fig. 6, d–f, depicts results without
physical inhibition and shows that, in this case, a 100-fold
reduction in fVIII or fIX leads to virtually no reduction in
thrombin concentration after 600 sec.
Fig. 7 shows the time course of different platelet and
enzyme concentrations under normal conditions with phys-
ical inhibition of TFVIIa activity. In Fig. 7 a, we see that
the concentration of platelets adherent to the subendothe-
lium, [PLas], increases until complete surface coverage is
achieved at about 300–350 s. The concentration of activated
but not wall-adherent platelets, [PLav], increases more grad-
ually, and, while it is still rising after 600 s, at that time most
of the activated platelets are directly adherent to the suben-
dothelium, i.e., the platelets form an approximate mono-
layer. The concentration of unactivated platelets [PL] ini-
tially drops due to activation of platelets (primarily by
contact with the subendothelium) and then climbs back to
its plasma value.
Fig. 7 b shows the decrease of exposed TF molecules as
platelets deposit on the subendothelium, and the initial rise
and then decline of TFVII complexes. Note that after about
20 s, most of the exposed TF is bound by fVII. The inset
shows semilog plots of the densities of the TFVII,
TFVIIa, and TFVIIaTFPIXa complexes. The TFVIIa
density remains roughly 1% of the TFVII density, and
decreases, at first gradually and then sharply coincident with
the coverage of subendothelium by platelets. Very little of
the decrease can be attributed to inhibition of TFVIIa by
TFPIXa as the density of the inhibited TFVIIa complex
(TFVIIaTFPIXa) remains four orders of magnitude less
FIGURE 7 Time course of enzyme and platelet concentrations when platelet deposition blocks TFVIIa activity, standard parameter values are used, the
shear rate is 100 s1, and the TF density is 15 fmol/cm2. (a) Wall-adherent (PLAS), activated (PLAV), and unactivated (PL) platelet concentrations. (b)
TF (total) and TFVII densities, and (inset) TFVII, TFVIIa, and TFVIIaTFPIXa densities. (c) Plasma fVIIIa and fIXa concentrations and
platelet-bound tenase (VIIIaIXa) complex concentration. (d) Plasma fVa, fXa, and thrombin concentrations and platelet-bound prothrombinase (VaXa)
concentration. Note that PLAS, PLAV, and PL correspond to the model variables [PLas], [PLav], and [PL] but are expressed in plt/mm3.
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than the density of uninhibited TFVIIa even as the latter
decreases. The inhibition of TFVIIa here is almost com-
pletely due to the deposition of platelets on the subendothe-
lium. Fig. 7 c shows that the plasma fVIIIa increases by
more than a factor of 104, while the plasma fIXa concen-
tration decreases sharply as platelets depositing on the sub-
endothelium cover the TFVIIa complex that activates IX to
IXa. The concentration of the platelet-bound VIIIaIXa
(tenase) complex increases in parallel with the increase of
the fVIIIa concentration until the drop in fIXa makes it the
limiting species in VIIIaIXa formation. After this, the
concentration of VIIIaIXa drops, but only slowly because
of the high affinity with which it is bound to the platelet
surface. Fig. 7d shows that after an initial sharp increase, the
plasma fXa concentration varies slowly and over a narrow
range during the remainder of the simulation. The concen-
trations of plasma fV and thrombin and platelet-bound
VaXa (prothrombinase) complex increase rapidly between
200 and 240 s and then level off for the remainder of the
calculation. Our results are consistent with reports (van’t
Veer and Mann, 1997) that there are two phases leading up
to substantial thrombin production; an initiation phase dur-
ing which fVa and fVIIIa are becoming available and little
thrombin is produced, and a propagation phase in which
substantial prothrombinase activity leads to large amounts
of thrombin production. Reduction in the level of inhibition
(see next paragraph) shortens the length of the initiation
phase, as does an increase (not shown) of the TF density to
levels well beyond the threshold value. We note that
throughout these calculations, zymogen levels in the bound-
ary layer differ only slightly from their initial or upstream
values, indicating that reactions are not transport-limited.
Fig. 8 shows results for the case in which platelet depo-
sition does not block TFVIIa activity. As seen in Fig. 8 a,
FIGURE 8 Time course of enzyme and platelet concentrations when platelet deposition does not block TFVIIa activity, standard parameter values are
used, the shear rate is 100 s1, and the TF density is 15 fmol/cm2. (a) Wall-adherent (PLAS), activated (PLAV), and unactivated (PL) platelet
concentrations. (b) TF (total) and TFVII densities, and (inset) TFVII, TFVIIa, and TFVIIaTFPIXa densities. (c) Plasma fVIIIa and fIXa
concentrations and platelet-bound VIIIaIXa (tenase) complex concentration. (d) Plasma fVa, fXa, and thrombin concentrations and platelet-bound VaXa
(prothrombinase) concentration.
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the evolution of the different platelet populations is very
similar to that in Fig. 7 a, while Fig. 8 b shows that, in
contrast, the time course of the TF complexes is very
different. The density of exposed TF molecules remains
constant throughout the calculation, and the TFVII density
increases sharply as almost all of the TF molecules are
bound by fVII, and then decreases fivefold during the re-
mainder of the simulation, due to continuing TFVII acti-
vation. The density of TFVIIaTFPIXa also continues to
increase but is never more than about 1% of the total
TFVIIa density. Thus TFPIXa inhibition of TFVIIa is
not effective, the TFVIIa complex continues to activate
fIX and fX throughout the simulation, and the concentra-
tions of fIXa and fXa continue to increase.
Dependence on platelet count
Clinically it is observed (Warkentin and Kelton, 1994) that
a decrease in platelet count, thrombocytopenia, by a factor
of 10 or more may lead to hemorrhage, with the severity of
the problem increasing the smaller the platelet concentra-
tion. A decrease in platelet count from 250,000 to 20,000
plt/mm3 usually does not cause severe enough symptoms
for treatment by platelet transfusion (White et al., 1994). In
the experiments depicted in Fig. 9, the effect of variations in
platelet count on model results is examined at shear rate 500
s1 and TF density of 15 fmol/cm2. Results for shear rate
100 and 1500 s1 are similar.
Fig. 9 a shows that the normal sharp rise in thrombin
concentration is delayed by about 100 sec for 10% of
normal platelet count (NPC), and that for 1% NPC, the
thrombin concentration remains substantially below normal.
Fig. 9 b shows that for NPC about 90% of the subendothe-
lium is covered by adherent platelets in about 300 s and
almost 100% is covered within 400 s. With platelet count
10% of normal, platelet coverage after 600 s is only 40%,
and for 1% NPC, the subendothelium is only sparsely cov-
ered (	7%) after 600 s. Reflecting the model’s physical
inhibition of subendothelial-bound complexes, the concen-
tration of TFVIIa drops sharply for NPC (see Fig. 9 c), but
continues to rise gradually for platelet counts 10% or 1% of
normal as new activation of TFVII outpaces the slower
rate of physical inhibition of TFVIIa because of slower
subendothelial coverage by adherent platelets.
Fig. 9, d and e, shows that the tenase concentration for
10% NPC eventually exceeds that for NPC, and that the
prothrombinase concentrations in the two cases plateau at
the same level. For 1% NPC, although the concentrations of
these complexes are still rising after 10 min, they remain
two to four orders of magnitude below the corresponding
concentrations in the NPC and 10% NPC cases. We note
also that the rate of fIXa and fXa binding to platelets from
the plasma was much smaller than the rate at which these
enzymes were produced by TFVIIa, most of the TFVIIa-
activated fIXa and fXa was removed by the flow, and that
the rate of production of fXa on platelets by tenase was
substantially higher than the rate of binding of fXa to
platelets from plasma (except at 1% NPC).
Dependence on surface reactivity
As mentioned above, (Hubbell and McIntire, 1986) reported
threefold faster platelet deposition on a collagen-coated
glass surface than that we extrapolated from studies on
subendothelium. It is likely that severe vascular injury ex-
poses surfaces that are more platelet-reactive (Badimon et
al., 1988; Mailhac et al., 1994) than the matrix exposed in
typical subendothelial studies (Turitto and Baumgartner,
1979) and for which Hubbell’s data might be more repre-
sentative. For this reason, we performed simulations differ-
ing from those described above only in that the rate of
platelet reaction with the wall, kpla , was taken to be 10-fold
larger, which leads to about threefold faster coverage of the
surface. For brevity, we refer to these simulations as fast-
surface experiments and the ones above as standard-surface
experiments. Notable differences in results are that for the
fast-surface experiments a much higher TF density is re-
quired to elicit a strong response (compare Fig. 10 a with
FIGURE 9 Time course of various concentrations for normal platelet count (250,000 plt/mm3), 10% of normal, and 1% of normal at shear rate 500 s1
and TF density of 15 fmol/cm2. (a) Thrombin concentration. (b) Percent of subendothelium covered by platelets. (c) TFVIIa concentration. (d)
Concentration of tenase VIIIaIXa on platelets. (e) Concentration of prothrombinase VaXa on platelets.
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Fig. 4 a) and that there is a larger spread between the
required TF densities for different shear rates. For the fol-
lowing experiments we used a TF density of 100 fmol/cm2
to obtain a final thrombin concentration at shear rate 500
s1 the same as that obtained with a TF density of 15
fmol/cm2 in the standard-surface experiments.
Fig. 11 a shows that the system has a response very
similar to that for the standard surface when we simulate
hemophilia A or B by reducing fVIII or fIX, respectively, to
1% of its normal value. This is for the case that platelet
deposition physically inhibits the activity of subendothelial
complexes. In the case (not shown) without physical inhi-
FIGURE 10 Dependence of thrombin concentration at 600 s on the density of TF on the subendothelium at shear rates of 100, 500, and 1500 s1. (a)
IXa-specific binding sites and fast-surface. (b) Shared IX/IXa binding sites and standard-surface. (c) Shared IX/IXa binding sites and fast-surface. Note
differences in horizontal scale.
FIGURE 11 Fast surface, shear rate 500 s1, and TF density of 100 fmol/cm2. (a–e) For normal platelet count (250,000 plt/mm3), 10% of normal, and
1% of normal, time course of (a) Thrombin concentration. (b) Percent of subendothelium covered by platelets. (c) TFVIIa concentration. (d) Concentration
of VIIIaIXa on platelets. (e) Concentration of VaXa on platelets. (f) For different levels of fVIII and fIX, time course of thrombin concentration. Normal,
HemA, and HemB have the same meaning as in Fig. 6.
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bition, the thrombin levels for normal blood and for hemo-
philias A and B are virtually indistinguishable from 200 s
until the end of the simulation at 600 s. For the fast surface,
time course plots (not shown) for normal blood are similar
to those shown in Fig. 7 for the standard surface, except that
the increases in the concentrations fVa, fVIIIa, tenase, pro-
thrombinase, and thrombin are sharper and occur earlier, at
about 80–100 s compared with 240–270 s.
By contrast, the behavior of the system with the fast
surface when the platelet count is reduced is very different
from that for the standard surface. Fig. 11 b shows that, for
the fast surface, the time course of the thrombin buildup is
very similar for all platelet counts, and that the final throm-
bin concentrations achieved are also very similar, with
thrombin concentration slightly higher than normal for the
10% NPC experiment and about half of normal for the 1%
NPC experiment. This contrasts with the more than four
orders of magnitude reduction of thrombin production with
1% NPC for the standard surface. Fig. 11, b–e, shows the
time course of platelet surface coverage and TFVIIa,
VIIIaIXa and VaXa concentrations for this case. These
should be compared with Fig. 9, b–e, for the standard
surface. Not shown is that, for each platelet count, the
activated platelet concentration [PLas]  [PLav] rises much
more quickly for the fast surface, so that there are far more
activated platelets present at comparable times and at a
given platelet count than for the standard surface.
Effect of specific IXa binding sites
To examine the effect of having two populations of fIXa
binding sites on platelets, 250 specific IXa sites and 250
shared IX/IXa sites, we performed calculations with 500
shared sites and no specific sites. We drop the terms, un-
derlined in Eqs. 16, 18, 23, and 24, which pertain to the
specific sites, and we set Np9 to 500. From Fig. 10 b, which
shows how thrombin concentration varies with TF density
for the standard surface and only shared binding sites, we
see that a much higher TF density, 50 fmol/cm2, is required
to obtain thrombin levels close to those obtained with 15
fmol/cm2 in calculations with both kinds of IXa binding
sites (compare with Fig. 4 a). Similarly, comparison of Fig.
10 c with Fig. 10 a shows it takes a TF density of 400
fmol/cm2 on the fast surface and with only shared binding
sites to reach the same thrombin levels obtained at 100
fmol/cm2 on that surface with both kinds of IXa binding
sites. So for both kinds of surfaces, having only shared
IX/IXa binding sites on the platelets leads to a requirement
for substantially higher TF densities to elicit substantial
thrombin production. Fig. 12 a shows that for normal blood,
thrombin develops, at TF 50 fmol/cm2, much as it does for
the two-binding-site case at TF 15 fmol/cm2. Fig. 12 b
shows that thrombin levels are still much reduced for he-
mophilia A (fVIII deficiency), but are only slightly reduced
for the fIX deficiency of hemophilia B.
DISCUSSION
We have formulated a mathematical model of the tissue
factor pathway of blood coagulation that takes into account
plasma-phase and surface-bound enzymes and zymogens,
coagulation inhibitors, and activated and unactivated plate-
lets. It includes both plasma-phase and membrane-phase
reactions, and accounts for chemical and cellular transport
by flow and diffusion, albeit in a simplified way. Compu-
tational studies of the model support three main conclu-
sions: (1) The model system responds in a threshold manner
to changes in the availability of particular surface binding
sites; an increase in TF binding sites, as would occur with
vascular injury, dramatically changes the system’s produc-
tion of thrombin. (2) The model suggests that, at least for
small injuries, platelets adhering to and covering the sub-
endothelium, rather than chemical inhibitors, play the dom-
inant role in blocking the activity of the TFVIIa enzyme
complex. And this suggests that a role of the IXa-tenase
pathway for activating fX to fXa is to continue fXa produc-
FIGURE 12 Shared IX/IXa binding sites, standard surface, and a TF density of 50 fmol/cm2. Time course of thrombin concentration for (a) normal blood
and various shear rates, (b) different levels of fVIII and fIX and shear rate 500 s1. Normal, HemA, and HemB have the same meaning as in Fig. 6.
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tion after platelets have covered the subendothelial TFVIIa
complexes. (3) The model predicts severely reduced throm-
bin production for hemophilias A and B, but only if the
TFVIIa activation of fX to fXa has been substantially
blocked.
Threshold response
Our results (see Fig. 4 a) show a very sharp transition in the
model’s production of thrombin as the density of TF mol-
ecules exposed on the subendothelium is varied; a two- or
threefold change in TF density near the transition can in-
duce changes which raise the thrombin concentration by a
factor of 104. The location of the transition is affected by
flow and kinetic parameters, but the existence of the sharp
transition is robust over a range of realistic parameter val-
ues. Others have found thresholds in models of the coagu-
lation system, but our result is distinct in that the variable
(TF density) that controls the threshold is known to change
significantly when a vessel is injured. A threshold depen-
dence on TF concentration was recently found in the exper-
imental preparation of van’t Veer and Mann (1997).
Activation thresholds that can be adjusted by changes in
binding-site densities would be of profound importance to
the regulation of coagulation. Blood could normally circu-
late in a state in which the activation threshold condition is
not exceeded, and activated enzyme, say fVIIa, could safely
circulate without initiating explosive coagulation. In fact,
Morrissey (1995) presents evidence that about 1% of circu-
lating fVII is normally activated. Slight disruptions of the
endothelium that exposed small amounts of TF would not
lead to coagulation. But a trauma substantial enough to raise
the TF levels beyond the transition level would elicit a very
strong response, primed by the interaction of the circulating
fVIIa with the newly exposed TF. That response would be
localized to the immediate vicinity of surfaces on which the
binding-site density was high.
Presumably the vasculature is always subject to some
degree of localized endothelial disruption and, therefore, to
some exposed TF, and this could lead to the coagulation
system normally being in an idling state, as suggested in
Jesty and Nemerson (1995), in which low levels of thrombin
are continually produced. Consistent with this suggestion is
the difference between our model’s response to a high TF
density (15 fmol/cm2) in which the thrombin concentration
reaches 18–70 nM, depending on shear rate, compared to
that at a low TF density (1 fmol/cm2 at shear rate 100 s1),
in which the thrombin concentration reaches a maximum of
only 2  104 nM after about 1000 s and decays slowly
thereafter. In this simulation, platelets cover the exposed
subendothelium in about 300–400 s, and then thrombin
generation continues because of a low concentration of
prothrombinase on the adherent platelets.
Flow serves to bring new zymogens and platelets to the
injury and to carry away from it plasma-phase enzymes
produced in response to the injury. For the shear rates we
examined, the zymogen concentrations in the reaction shell
show a transient dip as the simulations start, but soon climb
back to near their plasma levels for the remainder of the
simulation. The small size of the injury contributes to this;
for large areas of injured tissue one would expect zymogen
utilization at the upstream portions of the injury to reduce
the concentration of zymogen available along the down-
stream portions. For our simulations, the main effect of
higher shear rates is faster removal of plasma-phase en-
zymes. This has an inhibitory effect on the system causing
the threshold level to shift upward at higher shear rate. Flow
has a similar role in the explicit threshold condition found
for the simpler system studied in Fogelson and Kuharsky
(1998). Primarily because of the flow, where an enzyme is
produced relative to where it does its work is very impor-
tant. The effectiveness of fXa made by TFVIIa is not equal
to that of fXa made by the VIIIaIXa complex, a point also
made by Hoffman et al. (1995), in that the former can be
washed away by the flow before it can reach the platelet
surface, whereas the latter is already where it needs to be to
participate in prothrombinase formation.
Our results also show (Fig. 4 b) that for high TF levels,
the system’s response can be further regulated by the den-
sities of platelet binding sites, with a sharp transition in
response at densities about half those reported in the liter-
ature. These results are preliminary because we changed all
platelet binding site densities together and so cannot yet say
whether particular types of sites contribute most to this
behavior. Even so, these results suggest a certain elegance
in platelet design: given the kinetic parameters of the plate-
let-related enzymes and cofactors (which determine the
transition values), the numbers of binding sites per platelet
are such that small variations (say 10–20%) in them have a
relatively small effect on thrombin production. Therefore, a
participating platelet’s contribution to the coagulation re-
sponse is fairly consistent from platelet to platelet. This
consistency is achieved with approximately the minimum
possible average number of binding sites per platelet; if the
average were, say, 75–80% of this number, then platelets
with even a slightly below-average number of binding sites
would make a greatly reduced contribution to coagulation.
Recently, Sumner et al. (1996) found a two- to threefold
variation in tenase and prothrombinase activity in the blood
of healthy volunteers, which they suggest may be due to
variations in specific platelet binding sites. Our simulations
suggest that these variations in activity could be accounted
for by a 10–20% variation in platelet binding site densities.
In our calculations, the effect of specific platelet binding
sites for fIXa is to shift the response threshold to lower TF
densities, to sharpen the response as the threshold is
crossed, and to reduce the variation between the threshold
levels for different shear rates. These can be understood in
terms of the relative ease with which any fIXa produced can
bind to platelet surfaces, compared to the situation when
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fIXa must compete with the more plentiful fIX for shared
binding sites. One can regard the presence of specific fIXa
binding sites as a way of tuning the coagulation system to be
more efficient in its use of fIXa. The body could exploit this
efficiency by producing less TF on vascular subsurfaces and
still get an adequate response to injury with normal blood.
In our calculations with specific IXa binding sites, a TF
density of 15 fmol/cm2 leads to nanomolar or higher throm-
bin concentrations at all shear rates considered, whereas a
TF density of 50 fmol/cm2 or more is required when only
shared IX/IXa binding sites are present. A disadvantage of
following this strategy is that the system is then more
severely affected when fIX is missing from the system, as in
hemophilia B (compare Fig. 6 and Fig. 12 b).
Platelet inhibition of TFVIIa
To our knowledge, the hypothesis that adherent platelets
physically inhibit the activity of vessel-bound enzymes like
TFVIIa is new. When our attempts to reproduce the great
reduction of thrombin production associated with hemo-
philia A and B failed, we determined that this failure was
due to continued significant production of fXa by the
TFVIIa complex on the subendothelium. This made the
alternative pathway to fXa production by the VIIIaIXa
complex on activated platelets superfluous. The main inhib-
itor of TFVIIa is regarded to be the plasma protein TFPI;
the TFPI molecule must be activated by binding to fXa to
become an effective inhibitor of TFVIIa (Baugh et al.,
1998). In our simulations, the concentration of TFPIXa
was too low to inhibit more than a small percentage of the
exposed TFVIIa molecules. This is the case even though
the affinity of binding fXa to TFPI is high (Kd  2  1011
M), as is that for the binding of XaTFPI to TFVIIa (Kd 
1010 M). In the calculations reported in Fig. 7, which
include platelet inhibition of the TFVIIa complex, the
plasma-phase fXa concentration peaked at about 0.03 nM
but was generally smaller, and the TFPIXa concentration
was never more than 2  105 nM. In calculations in which
platelets do not inhibit TFVIIa, the fXa concentration
reached as high as 1.5 nM (in 600 s), but the TFPIXa
concentration did not reach 0.02 nM. The concentration of
plasma-phase fXa within the reaction shell in our model is
very low because of rapid removal of Xa by the flow; its
rate of removal by flow almost equals its rate of activation
by TFVIIa. Hence, binding of Xa with TFPI within the
reaction shell was strongly limited, and the resulting levels
of TFPIXa were too low for this complex to compete
effectively with fX and fIX in binding to TFVIIa.
We are certainly not arguing that TFPI plays no inhibi-
tory role in coagulation. The reaction shell in our model is
small, covering a 10 m  10 m square of subendothe-
lium (although similar results were found for squares of side
20 or 40 m), and flow quickly carries plasma-phase en-
zymes downstream and out of the shell. The mean time that
a plasma-phase enzyme molecule spends in the shell is
about 0.05 s for a shear rate 100 s1 and proportionally less
for the higher shear rates. Also, the flow maintains the
zymogen level within the shell at approximately its bulk
level in the plasma. This combination keeps the concentra-
tion of TFPIXa low and the concentration of the zymogens
with which it competes high. The situation could be differ-
ent for the downstream section of a long region of exposed
subendothelium. Then fX and fIX concentrations near the
subendothelium might be depleted because of reactions
upstream, and fXa produced upstream could bind to TFPI
and inhibit TFVIIa further downstream. The balance could
also be different from that in our simulations in regions of
flow recirculation where the zymogen entry rate is reduced
and the residence time for locally produced enzyme is
higher.
Two recent papers suggest that membrane-associated fXa
and TFPIXa may be important. Baugh et al. (1998) spec-
ulate that fXa remains bound to (or near) the TFVIIa
molecule that activated it, and that TFPI then binds to this
ternary complex. This pathway to TFPIXaTFVIIa for-
mation differs from that previous studies support, and
would seem to imply slowed activation of fX because of the
continuing presence of fXa bound to TFVIIa. Salemink et
al. (1999) used preformed TFPIXa complex, showed that it
desorbs slowly from anionic phospholipid membranes, and
suggest that subendothelial-bound TFPIXa might provide
a pool of inhibitor for TFVIIa that is less subject to
removal by flow. They used exogenous TFPIXa at con-
centrations of up to 0.8 nM, which are much higher than
those produced in our simulations, and at a TF density, 2.5
fmol/cm2, lower than the threshold levels found in our
simulations. It therefore seems doubtful whether, under the
conditions of our current simulations, inclusion of fXa,
TFPI, and TFPIXa binding to the subendothelium would
have a significant effect on our results.
Intuitively, it seems quite plausible that as more platelets
adhere to the exposed subendothelium, and thereby cover
more and more of the TFVIIa molecules on it, there are
progressively fewer of these molecules available to interact
with fX and fIX. We are not aware of any experiments that
specifically address this hypothesis. It appears to be consis-
tent with observations made in perfusion studies by Weiss et
al. (1986), using blood from a Scott syndrome patient whose
platelets aggregated normally but had reduced fXa binding
capacity and reduced ability to activate prothrombin in the
presence of fVa and fXa and to activate fX in the presence
of fVIIIa and fIXa. Whereas for normal blood, Weiss et al.
observed an increase in both platelet surface coverage and
fibrinopeptide A production (FPA is a by-product of cleav-
age of fibrinogen into fibrin by thrombin) with increased
perfusion time, for Scott syndrome blood, platelet adhesion
increased substantially with perfusion time, and this was
accompanied by a dramatic decrease in FPA production.
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Hemophilias
In the case that adherent platelets block TFVIIa activity,
the model produces results consistent with clinical observa-
tions on patients with hemophilias A and B. For both
hemophilias, the thrombin concentration is substantially
reduced, and the reduction in hemophilia A is more severe
than in hemophilia B. We also see (cf. Fig. 6, a–c) that early
in the process, the amount of thrombin produced in hemo-
philia A is indistinguishable from that produced in normal
blood, and that the thrombin concentration in hemophilia B
is actually higher than normal. In hemophilia B, the reduced
concentration of fIX means that fX has less competition for
activation by TFVIIa, so the early rate of fXa production is
higher, and this leads to somewhat greater prothrombinase
formation and thrombin production. In normal blood, the
activation of fIXa and formation of tenase soon produces
enough fXa on the platelet surfaces to overcome this initial
lag, but, of course, this does not happen in hemophilia B.
We note also that the amount of time before the normal
blood thrombin concentration exceeds that in hemophilia B
blood decreases with increasing shear rate, and that the
severity of the eventual deficit of thrombin production in
both hemophilia A and B increases with increasing shear
rate. Both observations reflect the fact that fXa activated on
the subendothelium must travel through the plasma to bind
to platelet surfaces and form prothrombinase. At higher
shear rates, more of this fXa is carried downstream before it
can bind to platelets. Again, in normal blood, this effect is
largely overcome by the production of fXa on the platelet
surface by platelet-bound tenase.
Reduced platelet count
The effects of reduced platelet count (thrombocytopenia)
for the standard (Fig. 9) and fast (Fig. 11, a–e) surface
illustrate the kinds of balances that influence how much
thrombin is produced. They show also that there are two
parameters that reflect surface reactivity: the TF density
(and associated kinetic parameters) and the rate constant kpla
for platelet activation by and adhesion to the surface. For the
standard surface at NPC, complete platelet coverage of the
surface occurs in about 5 min, and a TF density of 15
fmol/cm2 is just above threshold. When the platelet count is
reduced to 10% or 1% NPC, the surface becomes covered
by platelets much more slowly, so TFVIIa activity contin-
ues. On the other hand, the number of activated platelets,
along with their pro-coagulant membranes, decreases. For
10% NPC, the continued production of fIXa and fXa by
TFVIIa balances the slower deposition of platelets, and
after a delay of about 100 sec, the prothrombinase and
thrombin concentrations reach almost their levels for NPC.
For 1% NPC, the decreased number of activated platelets is
too great, so that despite the continued TFVIIa activity, the
levels of tenase, prothrombinase, and consequently throm-
bin remain very low. These balances are different on the fast
surface where, at NPC, complete surface coverage occurs in
about 100 s, and a TF density of 100 fmol/cm2 is just above
threshold. Reduction in platelet count again results in
slower surface coverage and continuing TFVIIa activity.
The high TF density leads to fIXa and fXa concentrations
that reach peaks 10–100 times larger than those for NPC on
the fast surface (and also 10–100 times those at all platelet
counts for the standard surface). In this case, the high
platelet reactivity of the surface results in rapid activation of
platelets (even at reduced platelet counts), thus providing
ample surface sites for tenase and prothrombinase formation
and consequently high thrombin production. For 10% NPC,
the balance among these factors leads to a slightly faster
than normal rise in thrombin concentration, whereas for 1%
NPC, this rise is slightly slower than normal.
Limitations and extensions
A model with more than 50 differential equations and a
corresponding number of kinetic and other parameters is
sure to prompt the question of whether essentially any
experimental observation could be fit by adjusting parame-
ter values appropriately. This is a reasonable question, and
so we wish to emphasize that all kinetic constants and
concentrations used in this paper are based on the literature;
no fitting was done. When complete kinetic data was not
available, we proceeded as described in Model Assumptions
above to obtain the parameter values used in this paper. For
simulations performed with other values of these parameters
that were consistent with literature data, the results were
qualitatively similar, but quantitative details such as the
threshold level of TF density changed.
The model studied here makes the explicit assumption
that chemicals and cells in the reaction region are well
mixed, and, based on this, uses a relatively simple model for
flow-mediated and diffusive transport. Of course this is a
simplification, and it has some consequences. One is that
the effective volume concentration of wall-bound chemi-
cals, such as TF, is a function of the flow velocity. This is
because the boundary layer thickness depends on flow ve-
locity, and because we have assumed that all cells and
chemicals, including those on the vessel wall, are distrib-
uted uniformly in the boundary layer. Because the boundary
layer thickness depends on the cube-root of velocity, the
effective TF volume concentration for any particular TF
surface density at shear rate 500 s1 is 51/3  1.7 times that
at shear rate 100 s1, and 31/3 0.7 times that at shear rate
1500 s1. These are fairly modest effects, but they make it
more difficult to make comparisons between our results at
different shear rates. The assumption that things within the
boundary layer are well mixed would be a poor one if very
slow diffusive transport led to substantial depletion of
chemicals or cells in the boundary layer. This does not occur
in any situation considered in this paper; in fact, zymogen
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levels within the boundary layer are reduced only slightly
from their bulk-plasma values. The assumption of well-
mixedness becomes suspect for large reaction regions be-
cause of the potential effects of upstream zymogen and
platelet depletion, and the downstream effect of enzymes
produced upstream. The calculations shown in the paper are
all for an injury of size 10 m  10 m, but the fact that
similar results were obtained for square injuries of sides 20
and 40 m, gives us confidence that the results for the
smaller injuries are reasonable.
The model studied in this paper is the first we are aware
of that combines a fairly comprehensive description of
coagulation biochemistry, interactions between platelets
and coagulation proteins, explicit treatment of protein bind-
ing site densities, and effects of chemical and cellular trans-
port. We think it has potential to give new insights into the
dynamics of hemostasis and thrombosis. Still it is limited in
assuming spatial homogeneity and in its simple treatment of
flow, so we are also working to develop models which allow
for spatial heterogeneity, on either a macroscopic (vessel
scale) or microscopic (cell scale) level, and which incorpo-
rate the effect of realistic multidimensional blood flow and
transport. Allowing for realistic flow and spatial heteroge-
neity requires solving the partial differential equations that
govern fluid motion and chemical transport inside of a
vessel whose geometry is made complex by the presence of
wall-adherent platelets or atherosclerotic plaque. These are
very challenging problems whose solution will be facilitated
using the computational techniques we have developed for
our ongoing studies of the dynamics of platelet aggregation
(Fogelson, 1992; Fogelson and Eyre, 1997; Wang and Fo-
gelson, 1999; Yu, 2000). Preliminary work along these lines
can be found in Kuharsky (1998).
APPENDIX A
Boundary layer thickness and (kflow
c , kflow
p )
We define the chemical boundary layer as the region from inside of which
zymogens and enzymes can reach the exposed subendothelium when it is
not covered with activated platelets. To find an estimate of its thickness, we
equate the average time it would take a molecule starting at point (x, h) to
diffuse to the wall, h2/(2D), with the time it would take that molecule to be
washed past the injured region by the parabolic flow, (L  x)/V(h). Here,
h is the molecule’s distance from the wall, x is its axial location relative to
the upstream end of the injury, L is the length of the injury, D is the
molecular diffusivity, and V(h)  V  (h/R)  (2  h/R) is the velocity at
distance h from the wall when the midstream velocity is V. Solving the
equation (L  x)/V(h)  h2/2D under the assumption that h 		 2R gives
h(x) ((L x)  R  D/V)1/3. Then, averaging h(x) over the length (0 x
L) of the injury gives the average boundary layer thickness:
h 
3
4R  L  DV 
1/3
.
Using this expression, the effective rate of zymogen (enzyme) transport to
(from) the shell can be obtained by equating the rate at which the amount
of chemical in the layer changes to the rate at which flow brings the
chemical across the upstream (downstream) end of the layer:
hL W
dc
dt  2 VRh2Whc.
where c is the chemical concentration. Hence,
dc
dt 
V  h
R  L c.
So we set kflowc equal to the coefficient of c and arrive at the expression:
kflowc 
V  h
R  L
with h defined as above.
The parameter kflowp for platelets is defined by a similar expression,
except that h is replaced by 2  3 m, the distance at which platelets can
attach to other platelets.
Mass transfer coefficients derived in the literature include one found by
solving a steady-state advection-diffusion in a short tube with constant
concentration along the wall (Baldwin and Basmadjian, 1994; Cussler,
1984):
k 0.812VD2RL 
1/3
.
This coefficient has dimensions length/time compared with the dimensions
time1 for our parameter kflowc . The reason for this difference is that k refers
to transport to a surface, while kflowc refers to transport into a volume. To
see how the two coefficients are related, we divide k by the average
thickness h of the boundary layer, and find that
k/h  1.8134 V
2D
RL2
1/3.
Substituting the expression for h into the formula for kflowc , we find that
kflowc  34 V
2D
RL2
1/3
which, except for the constant factor 1.81, is the same as k/h .
APPENDIX B
Model equations
dz2
dt k2
onz2p2 z2mtot e2mtot k2offz2m kflowc z2out z2 (1)
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de2
dt k2
one2p2 z2mtot e2mtot k2offe2m k3 k3catZ7mE2 k3z7me2
k12cat k12Z5E2 k12z5e2 k18  k18catZ7E2
k18z7e2k14cat k14Z8E2 k14z8e2 kflowc e2 k2ine2 (2)
dz2m
dt  k2
onz2p2 z2mtot e2mtot k2offz2m k7z2mPRO k7Z2mPRO (3)
de2m
dt  k2
one2p2 z2mtot e2mtot k2offe2m k7catZ2mPRO
k13cat k13Z5mE2m k13z5me2mk15cat k15Z8mE2m k15z8me2m (4)
dz5
dt k5
onz5p5 z5mtot e5mtot k5offz5m k12z5e2 k12Z5E2
N5
dPLas PLav
dt  kflow
c z5out z5 (5)
de5
dt k5
one5p5 z5mtot e5mtot k5offe5m k12catZ5E2 kflowc e5 (6)
dz5m
dt  k5
onz5p5 z5mtot e5mtot k5offz5m k5z5me10m  k5Z5mE10m 
k13z5me2m k13Z5mE2m (7)
de5m
dt  k5
one5p5 z5mtot e5mtot k5offe5m k5catZ5mE10m 
k13catZ5mE2m kpro PRO kpro e5me10m  k16APCe5m k16APCE5m (8)
dz7
dt k7
onz7TF e7mtot z7mtot k7offz7m k1z7e10 k1Z7E10
k18Z7E2 kflowc z7out z7 (9)
de7
dt k7
one7TF e7mtot z7mtot k7offe7m k1catZ7E10
k18catZ7E2 kflowc e7out e7 (10)
dz7m
dt  k7
onz7TF e7mtot z7mtot k7offz7m k2z7me10 k2Z7mE10
k3z7me2 k3Z7mE2 z7m
p
1 p (11)
de7m
dt  k7
one7TF e7mtot z7mtot k7offe7m k2catZ7mE10 k3catZ7mE2
k8 k8catZ10E7m k8z10e7m k9 k9catZ9E7m k9z9e7m
k11TFPIE10e7m k11TFPIE10E7m e7m
p
1 p (12)
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dz8
dt k8
onz8p8 z8mtot e8mtot k8offz8m k14z8e2 k14Z8E2 kflowc z8out z8
(13)
de8
dt k8
one8p8 z8mtot e8mtot k8offe8m k14catZ8E2 kflowc e8 (14)
dz8m
dt  k8
onz8p8 z8mtot e8mtot k8offz8m k6z8me10m  k6Z8mE10m 
k15z8me2m k15Z8mE2m (15)
de8m
dt  k8
one8p8 z8mtot e8mtot k8offe8m k6catZ8mE10m  k15catZ8mE2m
kten TEN kten e8me9m k17APCe8m k17APCE8m
kten e8me9m, kten TEN* (16)
dz9
dt k9
onz9p9 z9mtot e9mtot k9offz9m k9z9e7m k9Z9E7m kflowc z9out z9
(17)
de9
dt k9
one9p9 z9mtot e9mtot k9offe9m k9catZ9E7m k9ine9 kflowc e9
k9one9p*9 e9m, TEN* Z10mTEN* k9offe9m, (18)
dz9m
dt  k9
onz9p9 z9mtot e9mtot k9offz9m (19)
de9m
dt  k9
one9p9 z9mtot e9mtot k9offe9m kten TEN kten e8me9m (20)
dz10
dt k10
onz10p10 e10mtot z10mtot k10offz10m  k8z10e7m k8Z10E7mkflowc z10out z10 (21)
de10
dt k10
one10p10 e10mtot z10mtot k10offe10m  k10TFPI  e10 k10TFPIE10
k1 k1catZ7E10 k1z7e10 k8catZ10E7m
k2 k2catZ7mE10 k2z7me10 k10in e10 kflowc e10 (22)
dz10m
dt  k10
onz10p10 e10mtot z10mtot k10offz10m  k4Z10mTEN k4z10m TEN
k10onz10TEN* k10offZ10mTEN* (23)
de10m
dt  k10
one10p10 e10mtot z10mtot k10offe10m  k5 k5catZ5mE10m  k5z5me10m
k6 k6catZ8mE10m  k6z8me10m  kpro PRO kpro e5me10m
k4catZ10mTEN k4catZ10mTEN* (24)
dTEN
dt  kten
 e8me9m kten TEN k4cat k4Z10mTEN k4z10m TEN (25)
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dPRO
dt  kpro
 e5me10m  kpro PRO k7cat k7Z2mPRO k7z2mPRO (26)
dZ2mPRO
dt  k7
z2mPRO k7 k7catZ2mPRO (27)
dZ5E2
dt  k12
z5e2 k12  k12catZ5E2 kflowc Z5E2 (28)
dZ5mE2m
dt  k13
z5me2m k13  k13catZ5mE2m (29)
dZ5mE10m 
dt  k5
z5me10m  k5 k5catZ5mE10m  (30)
dZ7mE2
dt  k3
z7me2 k3 k3catZ7mE2 Z7mE2
p
1 p (31)
dZ7E2
dt  k18
z7e2 k18  k18catZ7E2 kflowc Z7E2 (32)
dZ7E10
dt  k1
z7e10 k1 k1catZ7E10 kflowc Z7E10 (33)
dZ7mE10
dt  k2
z7me10 k2 k2catZ7mE10 Z7mE10
p
1 p (34)
dZ8E2
dt  k14
z8e2 k14  k14catZ8E2 kflowc Z8E2 (35)
dZ8mE2m
dt  k15
z8me2m k15  k15catZ8mE2m (36)
dZ8mE10m 
dt  k6
z8me10m  k6 k6catZ8mE10m  (37)
dZ9E7m
dt  k9
z9e7m k9 k9catZ9E7m Z9E7m
p
1 p (38)
dZ10E7m
dt  k8
z10e7m k8 k8catZ10E7m Z10E7m
p
1 p (39)
dZ10mTEN
dt  k4
z10m TEN k4 k4catZ10mTEN (40)
dAPC
dt  kapckflow
c e2t tlag k16APCe5m k16  k16catAPCE5m
k17APCe8m k17  k17catAPCE8m kflowc APC (41)
dAPCE5m
dt  k16
APCe5m k16  k16catAPCE5m (42)
dAPCE8m
dt  k17
APCe8m k17  k17catAPCE8m (43)
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dTFPI
dt k10
TFPI  e10 k10TFPIE10 kflowc TFPIout TFPI (44)
dTFPIE10
dt  k10
TFPI  e10 k10TFPIE10 k11TFPIE10E7m
k11TFPIE10e7m kflowc TFPIE10 (45)
dTFPIE10E7m
dt k11
TFPIE10E7m k11TFPIE10e7m TFPIE10E7m
p
1 p (46)
dPL
dt kpla
 psub PLasPL ke2
actPLAe2 kplaactPLas PLavPL kflowp PLout PL (47)
dPLas
dt  kpla
 psub PLasPL PLav kpla PLas (48)
dPLav
dt kpla
 psub PLasPLav kpla PLas ke2
actPLAe2 kplaactPLas PLavPL (49)
dTF
dt TF
p
1 p (50)
dp10
dt  N10
pl
dPLas PLav
dt (51)
dp5
dt  N5
pl
dPLas PLav
dt (52)
dp8
dt  N8
pl
dPLas PLav
dt (53)
dp9
dt  N9
pl
dPLas PLav
dt (54)
dp2
dt  N2
pl
dPLas PLav
dt (55)
de9m,
dt  k9
one9p*9 e9m, TEN* Z10mTEN* k9offe9m,kten TEN* kten e8me9m, (56)
dTEN*
dt  kten
 e8me9m, kten TEN* k4cat k4Z10mTEN* k4z10m TEN* (57)
dZ10mTEN*
dt  k4
z10m TEN* k4 k4catZ10mTEN* (58)
dp*9
dt  N9
pl,
dPLas PLav
dt (59)
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